ASMB

In March 2026, Assembly Biosciences reported year-end 2025 financial results, noting increased revenue from collaborative research with Gilead and a narrowed net loss; however, Gilead Sciences declined its option on ABI-4334, leading Assembly Biosciences to seek a new partner for the program. In May 2026, the company filed an 8-K related to interim Phase 1b results for ABI-5366, which showed a 94% reduction in HSV-2 viral shedding. In August 2026, Assembly Biosciences announced its second-quarter 2026 financial results, reporting a narrowed net loss and increased collaboration revenue from Gilead. A significant event was the completion of a $115 million gross financing, which, along with a $75 million Gilead collaboration extension payment expected in Q4 2026, is projected to fund operations into 2029. Gilead also selected GS-1179 (formerly ABI-1179) to advance into a Phase 2 clinical trial for recurrent genital herpes, with plans to evaluate it in broader prevention settings. Additionally, Assembly Biosciences expanded the clinical development of ABI-6250 into cholestatic liver diseases.